Empagliflozin promising in hyponatremia induced by Chronic Syndrome of Inappropriate Antidiuresis
Switzerland: According to clinical research on acid-base and electrolyte disorders, the sodium-glucose cotransporter 2 (SGLT2) inhibitor "Empagliflozin" proves to be a promising therapeutic option for the chronic syndrome of inappropriate antidiuresis (SIAD) induced hyponatremia. The possible explanation given behind this therapeutic effect is improvement in neurocognitive function.
The study's findings are published in the Journal of the American Society of Nephrology.
SIAD leads to hypotonic hyponatremia and is challenging to treat. The therapeutic modalities available remain limited, and there needs to be more data on their association with neurocognitive impairment.
There is a requirement for newer management options. SGLT2 inhibitor empagliflozin could be valuable in promoting osmotic diuresis by urinary glucose excretion.
Considering this, researchers investigated this background to investigate whether four weeks of empagliflozin treatment increases serum sodium levels and improves neurocognition.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.